A psoriasis drug is now approved to treat psoriatic arthrits in adults. READ MORE
A psoriasis drug is now approved to treat psoriatic arthrits in adults.
The prevalence of rheumatic immune-related adverse events in 524 patients with cancer who received immune checkpoint inhibitors was 6.6%, according to a single-center observational study published in Annals of the Rheumatic Diseases.
Approximately 40% of patients with rheumatoid arthritis with persistent moderate to high disease activity waited at least 90 days for adjustment of their DMARD therapy.
An international expert group has issued consensus-based recommendations on the use of biosimilars for rheumatologic diseases, focusing on cost, extrapolation, and switching between bio-originators and biosimilars.
Research in Review
A recent comparative effectiveness study examined the relationship of ACPA status and accrued economic burden for patients with rheumatoid arthritis.
Recent research suggests that 40% of older patients with rheumatoid arthritis still take opioids regularly as of 2014.
Researchers developed a method of identifying candidates for dose reduction of disease modifying anti-rheumatic drugs.
A cost-effectiveness analysis showed that patients with RA who switch from an antirheumatic drug to a biologic drug are likely to increase costs of care.
The first guidelines on the use of disease-modifying therapies in multiple sclerosis have been issued by the European Committee for Research and Treatment of Multiple Sclerosis and the European Academy of Neurology.